All News
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases.
Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓
Bruce Strober
#RNL2024
@RheumNow https://t.co/2yHHcOgTC8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Allosteric versus active site inhibition by JAK.
Never understood this better.
Thanks to Bruce Strober.
#RNL2024
@RheumNow https://t.co/r9hhHLO5oS
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAK safety and malignancy risk.
Great talk by kevin Winthrop.
#RNL2024
@RheumNow https://t.co/d7WRHJxrpM
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAK toxicity of interest.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/qdlJFKTUR8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
I am jealous of the derms who have topical JAKi!
Dr. Strober flaunts all the different JAKi he has at his disposal to treat derm diseases #RNL2024 @rheumnow https://t.co/qdMWCSA5I1
TheDaoIndex KDAO2011 ( View Tweet)
JAK and TYK2 signaling pathways.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/WxoZGCEL0z
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAKinib negatives.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/vVzSQMVa5a
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
"Any vacuolar interface dermatitis will respond to a JAKi" - Dr. B Strober noted JAKi will work for cutaneous lupus #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Winthrop avoid JAKi and TNFi in pts with chronic lung infections like MAI. #RNL2024 @rheumnow https://t.co/TfMa7hktL9
TheDaoIndex KDAO2011 ( View Tweet)
Do you check CPK on patients who are on JAK inhibitors? #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
For pts on JAKi needing vaccines; to avoid diminishing vaccine efficacy, Dr. Winthrop noted he treats a JAKi like he would MTX in that he holds the JAKi a week after vaccinating. #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl!
Dr. Winthrop holds JAKi for one week after vaccination.
#RNL2024 @RheumNow https://t.co/BLiKu8xX7t
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Strober's JAKi in dermatology takeaways!
- Consider this for AD
- Dose matters in terms of both efficacy and toxicity
- Consider combination tx
- Topical JAKi option for vitiligo, especially head and neck involvement (harder in hands and other areas)
#RNL2024 @RheumNow https://t.co/ZrPfpUF4Hz
Dr. Rachel Tate uptoTate ( View Tweet)
JAKi are being used in inflammatory skin disease other than psoriasis:
#HydradenitisSuppurativa, #alopecia, #AtopicDermatitis and #vitiligo
- Dr. B Strober #RNL2024 @rheumnow https://t.co/FzPyATPB93
TheDaoIndex KDAO2011 ( View Tweet)
Povorcitinib - JAK1 specific for Hidradenitis Suppurativa
Efficacy at 16 weeks, improvement of disease and draining tunnel count over PBO
Upadacitinib shown with benefit for HS, but not as dramatic JAK response as other derm conditions
#RNL2024 @RheumNow https://t.co/f2cxJbLi1I
Eric Dein ericdeinmd ( View Tweet)
Deucravacitinib takes longer to work for PsO compared to UPA, IL-17i or IL23i; it’s better than apremilast. Side effects w/TYK2i: acne, mild⬆️CK, but zoster & lipid issues aren't seen much, & no CV risk warnings; Dr. Strober doesn't follow labs w/TYK2i. #RNL2024 @rheumnow https://t.co/05jKqL4wdx
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl from #RNL2024 @RheumNow
Palmoplantar psoriasis is a great time for first-line JAK inhibitor - Ben Strober, Yale dermatology
JAK for atopic dermatitis - extremely rapid responses https://t.co/hHYdGl51n2
Links:
Eric Dein ericdeinmd ( View Tweet)
"If you are throwing a JAKi at these patients (see below) you are gonna make them better." Dr. Bruce Strober reporting on potential patients/disease states who may respond to JAKi. #RNL2024 @RheumNow https://t.co/bghPuszu5t
Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2024 @RheumNow
Bruce Strober on JAK in skin diseases - diverse benefits:
- PsO
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
- Vitiligo
- Lichen planus any many others https://t.co/I9XHVbFpvQ
Eric Dein ericdeinmd ( View Tweet)
“JAKi can be thrown at any inflammatory skin disease and will work!” Dr. B Strober admits he uses many off-label. #RNL2024 @rheumnow https://t.co/nWzW9rMcWL
TheDaoIndex KDAO2011 ( View Tweet)
